Theravance Biopharma (TBPH) has wrapped up FY 2025 with Q4 revenue of US$45.9 million and Basic EPS of US$1.20, alongside trailing 12 month revenue of US$107.5 million and Basic EPS of US$2.10. Over the past year, revenue has moved from US$64.4 million to US$107.5 million on a trailing 12 month basis, while Basic EPS shifted from a trailing 12 month loss of US$1.15 to a profit of US$2.10. This frames a clear turn in the earnings profile as margins improved.

See our full analysis for Theravance Biopharma.

With the headline numbers in place, the next step is to see how this earnings story lines up with the widely shared narratives around Theravance Biopharma and where the data starts to challenge those views.

Profit swing to US$105.9 million over the year

• On a trailing 12 month basis, net income shifted to a profit of US$105.9 million, compared with a loss of US$56.4 million a year earlier, while trailing revenue moved from US$64.4 million to US$107.5 million.
• Consensus narrative highlights YUPELRI and potential new products as key drivers of revenue and margin strength. The recent move into profitability fits that story in the short term. At the same time, the same view points out that growth is still centered on a relatively narrow set of assets and a reduced royalty base, so the heavy reliance on a few products and milestone payments leaves those new profits closely tied to how a small number of therapies perform.

Quarterly earnings now consistently positive

• Across FY 2025, Theravance Biopharma reported quarterly Basic EPS of US$1.20, US$0.07, US$1.09, and a loss of US$0.27, reversing losses of US$0.31 and US$0.26 in the same quarters of FY 2024, with net income in Q4 FY 2025 at US$61.0 million compared with a loss of US$15.5 million in Q4 FY 2024.
• Bulls argue that disciplined spending and higher margin revenue can support stronger shareholder returns, and the pattern of three profitable quarters out of four in FY 2025 backs that in the near term. However, the earlier quarterly loss and the dependence on a small number of drugs in the bullish story mean this profit run still needs to prove it can hold up if any one product falls short.
  • The five year context of 49% yearly earnings growth supports the bullish claim that the business can scale earnings, but the fact that profitability emerged only recently means those growth percentages are coming off a low base.
  • Bullish commentary also leans on future milestones and rare disease pricing, whereas the current figures show profitability is closely linked to recent revenue of US$107.5 million and the wind down of external royalty streams, which may not repeat in the same way.

Bulls say the latest profit run could be the start of a much stronger phase for the business, so if you want to see how that argument stacks up against the detailed earnings and margin assumptions, it is worth reading the full bullish case for Theravance Biopharma: 🐂 Theravance Biopharma Bull Case

Mixed signals on growth and valuation

• The trailing 12 month revenue growth rate of 0.7% and a P/E of 23.9x sit alongside a current share price of US$14.01, compared with a DCF fair value of about US$15.45 and an analyst price target of US$15.83. The P/E is lower than the cited peer average of 42x but higher than the US Pharmaceuticals industry at 18x.
• Bears focus on modest revenue growth and forecast earnings pressure, and that view is echoed by the 0.7% trailing revenue growth rate and the comment that analysts expect earnings to decline by 14.2% a year over the next three years. At the same time, the current P/E at 23.9x is below the peer average and the share price sits under both the DCF fair value and the price target, which means the market is already valuing the company at a discount to those reference points while still pricing it richer than the broader industry.

Skeptics see the slow revenue growth and projected earnings decline as key reasons to be cautious, so if you want to unpack that side of the argument in more detail, it is worth reading through the bear case on Theravance Biopharma: 🐻 Theravance Biopharma Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Theravance Biopharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both cautious and optimistic angles on Theravance Biopharma now on the table, the real question is how the trade off looks to you. If you want to see the balance of concerns and potential upsides laid out clearly, take a closer look at the 2 key rewards and 1 important warning sign

See What Else Is Out There

Theravance Biopharma's modest 0.7% revenue growth, projected 14.2% yearly earnings decline, and dependence on a few products leave its progress looking fragile.

If that concentration risk and slowdown worries you, compare it with companies screened for stronger perceived value and healthier fundamentals using the 48 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.